This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
192
Moxifloxacin 400 mg once orally daily
Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae
Time frame: Days 1, 2, 3 of treatment
Patient-reported symptom improvement using SNOT-16 questionnaire
Time frame: Up to End of Treatment (Day 10-13)
Clinical Response
Time frame: End of Treatment
Bacteriological Response
Time frame: End of Treatment
Activity Impairment Assessment questionnaire
Time frame: Up to End of Treatment (Day 10-13)
Incidence of Premature Termination
Time frame: Premature Termination
Adverse Events Collection
Time frame: Up to End of Treatment (Day 10-13)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Hoover, Alabama, United States
Unnamed facility
Jonesboro, Arkansas, United States
Unnamed facility
Searcy, Arkansas, United States
Unnamed facility
Fresno, California, United States
Unnamed facility
Riverside, California, United States
Unnamed facility
San Francisco, California, United States
Unnamed facility
Colorado Springs, Colorado, United States
Unnamed facility
Longmont, Colorado, United States
Unnamed facility
Bridgeport, Connecticut, United States
...and 25 more locations